1. Home
  2. CSTL vs TRIN Comparison

CSTL vs TRIN Comparison

Compare CSTL & TRIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Castle Biosciences Inc.

CSTL

Castle Biosciences Inc.

N/A

Current Price

$32.44

Market Cap

1.2B

Sector

Health Care

ML Signal

N/A

Logo Trinity Capital Inc.

TRIN

Trinity Capital Inc.

N/A

Current Price

$15.98

Market Cap

1.3B

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
CSTL
TRIN
Founded
2007
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Finance/Investors Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.3B
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
CSTL
TRIN
Price
$32.44
$15.98
Analyst Decision
Strong Buy
Buy
Analyst Count
6
5
Target Price
$46.67
$16.00
AVG Volume (30 Days)
407.5K
1.3M
Earning Date
02-26-2026
02-25-2026
Dividend Yield
N/A
12.77%
EPS Growth
N/A
25.79
EPS
N/A
2.17
Revenue
$343,530,000.00
$268,271,000.00
Revenue This Year
$2.88
$31.25
Revenue Next Year
N/A
$16.06
P/E Ratio
N/A
$7.38
Revenue Growth
10.15
30.76
52 Week Low
$14.59
$12.50
52 Week High
$44.28
$17.20

Technical Indicators

Market Signals
Indicator
CSTL
TRIN
Relative Strength Index (RSI) 24.66 45.61
Support Level $38.20 $16.16
Resistance Level $40.88 $16.61
Average True Range (ATR) 1.98 0.39
MACD -1.10 -0.12
Stochastic Oscillator 3.79 1.48

Price Performance

Historical Comparison
CSTL
TRIN

About CSTL Castle Biosciences Inc.

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.

About TRIN Trinity Capital Inc.

Trinity Capital Inc is a closed-end, non-diversified management investment company. The company is engaged in providing debt, including loans and equipment financings, to growth-stage companies, including venture-backed companies and companies with institutional equity investors. Its equipment financings involve loans for general or specific use, including acquiring equipment, secured by the equipment or other assets of the portfolio company.

Share on Social Networks: